Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Spherix Global Insights

< Previous 1 2 3 Next >
Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
From Spherix Global Insights
Via GlobeNewswire
New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments
From Spherix Global Insights
Via GlobeNewswire
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
From Spherix Global Insights
Via GlobeNewswire
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
From Spherix Global Insights
Via GlobeNewswire
Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
From Spherix Global Insights
Via GlobeNewswire
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights' Tucker Hurtado Recognized as Luminary by Healthcare Businesswomen’s Association
From Spherix Global Insights
Via GlobeNewswire
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
US Hematologists Show Cautious Optimism as Data Reveal Early Adoption Trends for Hympavzi (Pfizer) and Alhemo (Novo Nordisk) in Hemophilia A and B, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights and the American Kidney Fund Announce Strategic Partnership and Inaugural Initiative to Elevate the Voice of Kidney Patients – Beginning with IgAN Patients
From Spherix Global Insights
Via GlobeNewswire
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
From Spherix Global Insights
Via GlobeNewswire
Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization
From Spherix Global Insights
Via GlobeNewswire
FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Patient Chart Audit Reveals Changing Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Dynamics As New Competition Challenges Alexion/Astra Zeneca's Soliris and Ultomiris
From Spherix Global Insights
Via GlobeNewswire
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
From Spherix Global Insights
Via GlobeNewswire
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.